A Phase 1, Multiple Dose, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pharmacokinetics, Safety and Tolerability of AMG 416 Administered Intravenously to Chinese Subjects With Chronic Kidney Disease on Hemodialysis
Latest Information Update: 19 Nov 2021
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Amgen
- 10 Nov 2021 Results published in the Clinical Therapeutics
- 07 Feb 2019 Status changed from active, no longer recruiting to completed.
- 21 Dec 2018 Status changed from recruiting to active, no longer recruiting.